
The drugmaker cited Germany’s planned price cuts for medicines as it paused future investment decisions in the country.
Roche has paused all future investment decisions in Germany, the company’s Germany head, Daniel Steiners, told Die Welt. The announcement came as Berlin hosted a summit aimed at attracting business investment.
The decision follows a law passed by Germany’s parliament in July to control costs in the statutory health insurance system. Under the law, drugmakers will have to offer discounts of 15.5% on most branded medicines from next year, up from 7% currently, according to Euronews.
Economy Minister Katherina Reiche said the measures were needed to control social security contributions, while praising the pharmaceutical sector’s contribution. Siemens chief executive Roland Busch called Roche’s move a warning, saying companies may shift investment if conditions in Germany are unsuitable.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.